Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Common Equity (2022 - 2026)

Cannabis Bioscience International Holdings filings provide 5 years of Common Equity readings, the most recent being -$1.5 million for Q1 2026.

  • On a quarterly basis, Common Equity fell 19.71% to -$1.5 million in Q1 2026 year-over-year; TTM through Feb 2026 was -$1.5 million, a 19.71% decrease, with the full-year FY2025 number at -$1.2 million, down 7.84% from a year prior.
  • Common Equity reached -$1.5 million in Q1 2026 per CBIH's latest filing, down from -$1.4 million in the prior quarter.
  • The five-year high for Common Equity was -$405301.0 in Q4 2022, with the low at -$1.5 million in Q1 2026.
  • A 5-year average of -$982067.9 and a median of -$1.1 million in 2024 define the central range for Common Equity.
  • Year-over-year, Common Equity crashed 107.72% in 2023 and then fell 7.84% in 2025.
  • Year by year, Common Equity stood at -$405301.0 in 2022, then crashed by 107.72% to -$841886.0 in 2023, then crashed by 34.8% to -$1.1 million in 2024, then dropped by 20.12% to -$1.4 million in 2025, then dropped by 7.62% to -$1.5 million in 2026.
  • Per Business Quant, the three most recent readings for CBIH's Common Equity are -$1.5 million (Q1 2026), -$1.4 million (Q4 2025), and -$1.2 million (Q3 2025).